Multitargeted bioactive ligands for PPARs discovered in the last decade
Jun Zhang,Xin Liu,Xian-Bin Xie,Xian-Chao Cheng,Run-Ling Wang
DOI: https://doi.org/10.1111/cbdd.12806
2016-01-01
Chemical Biology & Drug Design
Abstract:Type 2 diabetes took insulin resistance as the main clinical manifestation. PPARs have been reported to be the therapeutic targets of metabolic disorders, such as obesity, hypertension, diabetes, and cardiovascular disease. Previously, PPAR agonist rosiglitazone was restricted in clinic due to cardiomyocytes infarction, weight gain, and other serious side-effects, which were mainly due to the single and selective PPAR agonism. In recent years, multitarget-directed PPAR agonists with synergistic reaction as well as fewer side-effect have been the hot topic in designing promising agents. In this review, we updated and generalized the development of PPAR partial agonists, PPAR antagonists, PPAR/ dual agonists, PPAR partial agonists, PPAR antagonists, PPAR/ dual agonists, PPAR/ dual agonists, and PPAR// pan-agonists published in recent decade. Most of these molecules were modified from known structures or came from high-throughput screening. Among these molecules, some were expected to be promising drugs against metabolic disorders, while others seemed to provide new insight for designing novel PPAR agents.